MAP2K7 and type 2 diabetes mellitus: We found that reducing blood glucose levels by the administration of type 2 diabetes mellitus drug acarbose significantly enhanced sensitivity to MEK inhibitors trametinib, binimetinib and selumetinib in RAP tumours, providing a practical strategy to counteract drug metabolism within tumour cells that elevate RAS/WNT.